EAM Investors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

EAM Investors’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-23,126	Closed	-$1.18M	–	346
2020 Q1	$1.18M	Sell	23,126 -7,959	-26%	-$533K	0.37%	131
2019 Q4	$2.47M	Buy	+31,085	New	+$1.84M	0.54%	53
2018 Q2	–	Sell	-49,311	Closed	-$2.38M	–	379
2018 Q1	$2.38M	Buy	49,311 +3,851	+8%	+$215K	0.4%	127
2017 Q4	$1.79M	Sell	45,460 -23,501	-34%	-$878K	0.32%	150
2017 Q3	$2.14M	Sell	68,961 -20,789	-23%	-$585K	0.28%	178
2017 Q2	$2.46M	Sell	89,750 -6,475	-7%	-$193K	0.41%	126
2017 Q1	$3.55M	Buy	+96,225	New	+$2.42M	0.56%	44

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

EAM Investors's GBT Position: Q2 2020 in Review

EAM Investors sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2020, closing a stake of 23,126 shares — an estimated $1.18M sold.

EAM Investors first reported a position in GBT in Q1 2017 and held it in 7 quarters. The position peaked at $3.55M in Q1 2017. 253 funds tracked by Wall St. Rank hold GBT as of Q2 2020.

EAM Investors reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
EAM Investors sold 23,126 Global Blood Therapeutics, Inc. shares in Q2 2020, an estimated $1.18M.
EAM Investors first reported a position in Global Blood Therapeutics, Inc. in Q1 2017 and held it in 7 quarters.
EAM Investors's Global Blood Therapeutics, Inc. position peaked at $3.55M in Q1 2017.
253 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2020.

Based on EAM Investors's 13F filing for Q2 2020, filed 13 Aug 2020.